Trial Profile
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
- Acronyms PASCAL
- Sponsors UCB Biosciences
- 05 Apr 2024 Status changed from active, no longer recruiting to completed.
- 06 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 29 Mar 2024.
- 07 Nov 2023 Planned End Date changed from 1 Dec 2023 to 29 Mar 2024.